Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

July 11th 2018

Identifying Mutational Status in CLL

July 11th 2018

Diagnosing Chronic Lymphocytic Leukemia

July 11th 2018

Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.

July 11th 2018

Current Rectal Cancer Treatments Fall Short for Younger Patients With Advanced Disease

Surabhi Dangi-Garimella, PhD

Current standard of care treatment for rectal cancer, which recommends combining surgery with chemotherapy and radiation, fails to prolong survival in patients younger than 50 years of age, according to findings published early online in the journal Cancer.

July 10th 2018

Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR

Laura Joszt, MA

Ixazomib taken twice weekly with lenalidomide and dexamethasone resulted in high overall response rate (ORR) and a durable response among patients with newly diagnosed multiple myeloma (MM).

July 10th 2018

Narrow Networks in Cancer Care: Tough on Patients but Here to Stay

Mary Caffrey

Experts at the National Comprehensive Cancer Network Policy Summit discussed the present challenges of transitioning to alternative payment models at a time when the costs of many cancer therapies are rising.

July 8th 2018

Experts Suggest Prioritizing Price and Benefit, Allowing Negotiations for Targeted Cancer Drugs

Alison Rodriguez

Experts recently proposed 3 steps to promote targeted cancer drugs that yield clinical benefits while reducing overall price growth.

July 6th 2018

Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM

Laura Joszt, MA

Research presented at the 2018 American Society of Clinical Oncology Annual Meeting identified predictors of long-term survival and health-related quality of life (QoL) in patients with newly diagnosed multiple myeloma (MM).

July 6th 2018

Dr Peter Paul Yu on Progress in the Move Toward Interoperability

Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.

July 5th 2018

COA Protests Against the Medicare Part B Sequester Cut, Files Lawsuit

The Community Oncology Alliance (COA) has filed a lawsuit in the US District Court for the District of Columbia, stating that the 2% sequester cut to Medicare Part B drug reimbursement is unconstitutional and illegal, and that it can harm patient care and have a huge impact on the communityc ancer care system.

July 5th 2018

Study Suggests HPV Test More Accurate Than Pap Smear for Cervical Cancer Screening

Jaime Rosenberg

During the first round of screening, a human papillomavirus (HPV) test detected more abnormal cells grade 3 or worse in the cervix than a Papanicolau (Pap) smear, resulting in a lower liklihood of abnormal cells grade 3 or worse at 48 months.

July 5th 2018

BrainChild-01 Will Evaluate CAR T Cells in Pediatric CNS Tumors

Surabhi Dangi-Garimella, PhD

The trial is designed to test chimeric antigen receptor (CAR) T-cell therapy in children and young adults with relapsed/refractory brain and central nervous system (CNS) tumors, wherein the modified CAR T cells will be directly injected at the site of tumor resection or into the ventricular system of the CNS.

July 5th 2018

Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.

July 5th 2018

Review Finds Time to Diagnosis for Multiple Myeloma Can Be Significantly Reduced

Laura Joszt, MA

A review of studies found that the time from symptom onset to confirmation of diagnosis of multiple myeloma can be significantly reduced. Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.

July 3rd 2018

Feedback on the Direction, Challenges of the OCM

Laura Joszt, MA

Although most practices participating in CMS' Oncology Care Model (OCM) are among the most sophisticated in the country, they've run into challenges and have identified areas for adjustment in the 5-year pilot.

July 2nd 2018

First Immunotherapy Combination Demonstrates Improved PFS in Triple-Negative Breast Cancer

Jaime Rosenberg

Atezolizumab, in combination with chemotherapy, significantly reduced the risk of disease progression and mortality in patients with metastatic triple-negative breast cancer.

July 2nd 2018

Study Encourages Mixed Methods Research for Rare Disease Clinical Trials

Alison Rodriguez

Mixed methods research incorporating interviews found a high concordance between patient-reported qualitative data and assessed tumor response in patients with Merkel cell carcinoma.

July 2nd 2018

Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival

It’s been years since a large portion of colon cancer patients have seen any innovations in treatment. However, there are dietary and physical behavioral changes individuals can make that positively impact colon cancer survival said Leonard Saltz, MD, executive director of Clinical Value and Sustainability, head of Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center.

July 1st 2018

Challenges with Treating Merkel Cell Carcinoma and Other Rare Diseases

Alison Rodriguez

In an interview with Rare Disease Report®, Nicholas J. Robert, MD, of McKesson Specialty Health, discussed the challenges and advances involving treating with treating Merkel cell carcinoma.

June 30th 2018

Glasdegib Receives Priority Review Based on Results It Nearly Doubles OS in AML

Laura Joszt, MA

Based on trial results that showed glasdegib, an investigational oral smoothened inhibitor, nearly doubled overall survival (OS) in patients with previously untreated acute myeloid leukemia (AML), the FDA has granted the Pfizer drug a Priority Review.

June 30th 2018

Dr John Schorge Discusses Prevention Methods in Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.

June 29th 2018

Summer Reading List: Most Read AJMC® Articles of June

Jaime Rosenberg

We've rounded up the top 5 most read articles of June, including trial results from the 2018 American Society of Clinical Oncology Annual Meeting and a FDA breakthrough therapy designation for a gene therapy.

June 29th 2018

AbbVie and Calibr to Collaborate on CAR T-Cell Development

Samantha DiGrande

Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell therapies primarily aimed at treating cancer, particularly, solid tumors.

June 29th 2018

AJMC® in the Press, June 29, 2018

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

June 28th 2018

Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.

June 28th 2018

Dr Jamie Bakkum-Gamez on Developing an Early Detection Test for Endometrial Cancer

Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, discusses her research on developing an early detection test for endometrial cancer.

June 28th 2018

Tecentriq–Chemotherapy Combination Demonstrates Increased Survival in ES-SCLC

Samantha DiGrande

This week, drug maker Roche released positive data from its phase 3 IMpower133 study that investigated an immunotherapy-based combination of atezolizumab (Tecentriq) and chemotherapy in the treatment of extensive-stage small cell lung cancer (ES-SCLC).

June 27th 2018

Evidence-Based OncologyTM, an AJMC® Publication, Explores the Rise of Technology at the Point of Care

From the role of data in treatment decisions to the use of apps in tracking patient responses, technology is now front-and-center in cancer care. A special issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care®, explores the rise of point-of-care tools.

June 27th 2018

Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy

Laura Joszt, MA

Cancer cells can take advantage of the BCL-2 protein to survive chemotherapy, but a drug that suppresses BCL-2 may have promise in patients with leukemia who produce too much of the protein.

June 27th 2018

Exploring the Current State of Precision Medicine at the ASCO Annual Meeting

During this year's American Society of Clinical Oncology (ASCO) annual meeting, we sat down with 4 physicians to discuss their experiences with precision medicine, how it's changing oncology care, challenges associated with the shift, and where they think the future of precision medicine is headed.

...

44 45 46 47 48 49 50 51 52

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions